SHH:600223
Lushang Freda Pharmaceutical Co.,Ltd. · SHH · Real Estate · CNY · FY for 2025
Figures on this page computed 2026-11-07 23:07 UTC
Last close
n/aCNY
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
29.6xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
9.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
5.2%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
6.3%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
0.04Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
1.1%Dividend yield
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
What it pays out is the furthest below its sector's middle: 0.47 against 0.84 on the market's range.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales0.42x
Its own average over 10 years, 8.62B.
- Profit0.75x
Its own average over 10 years, 250.8M.
- Free cash flow0.23x
Its own average over 10 years, 998.5M.
- Debt0.02x
Its own average over 10 years, 7.33B.
- Pricen/a
Its own average over 0 years. Market data
Debt is furthest from its own average, at 0.02 times.
The filed years, as a table
10Each line is 100 at 2016-12-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2016-12-31 | 100.0 | 100.0 | 100.0 |
| 2017-12-31 | 108.4 | 138.6 | 96.0 |
| 2018-12-31 | 115.4 | 175.4 | 98.7 |
| 2019-12-31 | 134.6 | 373.0 | 97.5 |
| 2020-12-31 | 178.1 | 691.4 | 98.8 |
| 2021-12-31 | 161.7 | 391.8 | 100.7 |
| 2022-12-31 | 169.4 | 49.2 | 110.7 |
| 2023-12-31 | 59.9 | 328.4 | 98.5 |
| 2024-12-31 | 52.1 | 263.6 | 98.9 |
| 2025-12-31 | 47.4 | 203.3 | 99.0 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Figures behind the shape
Growth
-23.3%faster is higher, placed against 4,950 companies as of 2026-11-06
Five-year revenue growth rate-23.3%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Five-year EPS growth rate-22.2%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
One-year change in net income-22.9%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Returns on capital
9.7%higher is higher, placed against 5,089 companies as of 2026-11-06
Return on invested capital9.7%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity4.4%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets3.2%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Margins
50.9%wider is higher, placed against 3,412 companies as of 2026-11-06
Gross margin50.9%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin4.8%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin5.2%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin6.3%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Price
29.6xcheaper is higher, placed against 4,362 companies as of 2026-11-06
Price to earnings29.6x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
Price to book1.3x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDA6.5x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio1.5x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
Safety
0.04safer is higher, placed against 3,227 companies as of 2026-11-06
Debt to equity0.04
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio4.71
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage23.7x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score5.48
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
What it pays out
1.1%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-06
Dividend yield1.1%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Payout ratio32.5%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio3.7x
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.